Drug price review board bill
HR 1434, introduced by Rep. Durbin (D-Ill.) March 23, would establish a board, modeled on the Canadian price review board, that would collect pricing information and R&D, marketing and manufacturing costs, publish its findings, and give the board power to revoke a drug's patent if the price is found excessive. Durbin wants his proposal or a similar concept included in Clinton's health care package. The bill, which currently has four sponsors, was referred to the Energy & Commerce Committee.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth